{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:49:57Z","timestamp":1772084997538,"version":"3.50.1"},"reference-count":76,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Though numerous quality assurance (QA) measures are in place for the practice of gynecologic cytopathology, many of them are not clearly defined and may be variably used by laboratories worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess current practice patterns regarding the implementation of selected gynecologic cytology QA metrics to help develop guidance for laboratories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A supplemental questionnaire was mailed to laboratories participating in the 2022 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program requesting data regarding their QA measures in gynecologic cytology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>A total of 562 laboratories responded to the supplemental questionnaire; responses from 511 laboratories were analyzed further. Of 492 laboratories, most considered Papanicolaou (Pap) tests from patients with untreated abnormal cytology in the previous year (386; 78.5%) or with an abnormal gynecologic biopsy finding (concurrent or within the past year) (331; 67.3%) as high-risk for negative rescreening. Many laboratories (436 of 511; 85.3%) required pathologist review of Pap tests for indications other than reactive\/abnormal cells (eg, endometrial cells in women 45 years of age and older). For assessing cytologists\u2019 performance, 88.5% (399 of 451) of respondents recorded the discrepancy rate between cytologist\u2019s and pathologist\u2019s interpretations. For monitoring pathologists\u2019 performance, most laboratories (243 of 389; 62.5%) evaluated cases with significant cytologic-histologic discrepancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The CAP survey provided a detailed assessment of current QA practices regarding gynecologic cytology, which can aid laboratories in making decisions related to enhancement of QA in their setting. As the guidelines and tools for cervical cancer screening evolve, QA metrics will need to be accordingly refined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2025-0187-cp","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:17:31Z","timestamp":1759501051000},"page":"194-201","source":"Crossref","is-referenced-by-count":0,"title":["Practice Patterns Regarding Quality Assurance Measures in Gynecologic Cytology: Survey Results of Laboratories Participating in the 2022 College of American Pathologists PAP Education Program"],"prefix":"10.5858","volume":"150","author":[{"given":"Abha","family":"Goyal","sequence":"first","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York (Goyal)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane D.","family":"Davey","sequence":"additional","affiliation":[{"name":"the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Davey)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhona J.","family":"Souers","sequence":"additional","affiliation":[{"name":"Biostatistics Department, College of American Pathologists, Northfield, Illinois (Souers)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janie","family":"Roberson","sequence":"additional","affiliation":[{"name":"the Department of Pathology, The University of Alabama at Birmingham, Birmingham (Roberson)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Henry","sequence":"additional","affiliation":[{"name":"Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota (Henry)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna K.","family":"Russell","sequence":"additional","affiliation":[{"name":"the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York (Russell)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Teot","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Boston Children\u2019s Hospital, Boston, Massachusetts (Teot)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.","family":"Huang","sequence":"additional","affiliation":[{"name":"the Department of Laboratory Medicine and Pathology, University of Washington, Harborview Medical Center, Seattle (Huang)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana O.","family":"Tabbara","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Moffitt Cancer Center, Tampa, Florida (Tabbara)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-150-3-194-b01","article-title":"Clinical Laboratory Improvement Amendments (CLIA)","author":"Centers for Disease Control and Prevention","unstructured":"Centers for Disease Control and Prevention. Clinical Laboratory Improvement Amendments (CLIA). cdc.gov. https:\/\/www.cdc.gov\/clia\/php\/about\/#cdc_program_profile_policy-laws-and-regulations. Accessed October 28, 2024."},{"issue":"3","key":"i1543-2165-150-3-194-b02","series-title":"Clin Lab Med","first-page":"739","article-title":"Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part I","volume":"13","author":"Bachner","year":"1993","unstructured":"Bachner P,\nHamlin W. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part I. Clin Lab Med. 1993;13(3):739\u2013752."},{"issue":"4","key":"i1543-2165-150-3-194-b03","series-title":"Clin Lab Med","first-page":"987","article-title":"Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part II","volume":"13","author":"Bachner","year":"1993","unstructured":"Bachner P,\nHamlin W. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part II. Clin Lab Med. 1993;13(4):987\u2013994."},{"issue":"2","key":"i1543-2165-150-3-194-b04","series-title":"Arch Pathol Lab Med","first-page":"158","article-title":"College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization","volume":"137","author":"Tworek","year":"2013","unstructured":"Tworek JA,\nHenry MR,\nBlond B,\nJones BA. College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization. Arch Pathol Lab Med. 2013;137(2):158\u2013163."},{"issue":"1","key":"i1543-2165-150-3-194-b05","series-title":"Diagn Cytopathol","first-page":"84","article-title":"Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure","volume":"14","author":"Tabbara","year":"1996","unstructured":"Tabbara SO,\nSidawy MK. Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure. Diagn Cytopathol. 1996;14(1):84\u201386."},{"issue":"2","key":"i1543-2165-150-3-194-b06","series-title":"Clin Lab Manage Rev","first-page":"91","article-title":"The utility and cost-effectiveness of Pap test rescreening","volume":"12","author":"Raab","year":"1998","unstructured":"Raab SS. The utility and cost-effectiveness of Pap test rescreening. Clin Lab Manage Rev. 1998;12(2):91\u201396."},{"issue":"6","key":"i1543-2165-150-3-194-b07","series-title":"Am J Clin Pathol","first-page":"754","article-title":"Quality assurance in gynecologic cytology: what is practical","volume":"94","author":"Rohr","year":"1990","unstructured":"Rohr LR. Quality assurance in gynecologic cytology: what is practical? Am J Clin Pathol. 1990;94(6):754\u2013758."},{"issue":"4","key":"i1543-2165-150-3-194-b08","series-title":"Am J Clin Pathol","first-page":"494","article-title":"NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA: focused rescreening prior to report issuance, an enhanced quality control measure","volume":"141","author":"Cormier","year":"2014","unstructured":"Cormier K,\nSchaaf M,\nHamilton S,\nTickman RJ,\nPerez-Reyes N,\nSturgis CD. NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA: focused rescreening prior to report issuance, an enhanced quality control measure. Am J Clin Pathol. 2014;141(4):494\u2013500."},{"issue":"9B","key":"i1543-2165-150-3-194-b09","series-title":"J Cell Mol Med","first-page":"4051","article-title":"Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection","volume":"13","author":"Depuydt","year":"2009","unstructured":"Depuydt CE,\nArbyn M,\nBenoy IH,\nVandepitte J,\nVereecken AJ,\nBogers JJ. Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection? J Cell Mol Med. 2009;13(9B):4051\u20134060."},{"issue":"1","key":"i1543-2165-150-3-194-b10","series-title":"Cancer Cytopathol","first-page":"60","article-title":"Knowledge of the HPV status biases cytotechnologists\u2019 interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy","volume":"125","author":"Doxtader","year":"2017","unstructured":"Doxtader EE,\nBrainard JA,\nUnderwood D,\nChute DJ. Knowledge of the HPV status biases cytotechnologists\u2019 interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy. Cancer Cytopathol. 2017;125(1):60\u201369."},{"issue":"9","key":"i1543-2165-150-3-194-b11","series-title":"Arch Pathol Lab Med","first-page":"1182","article-title":"The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known","volume":"138","author":"Moriarty","year":"2014","unstructured":"Moriarty AT,\nNayar R,\nArnold T, et al. The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med. 2014;138(9):1182\u20131185."},{"issue":"6","key":"i1543-2165-150-3-194-b12","series-title":"J Am Soc Cytopathol","first-page":"558","article-title":"Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping","volume":"10","author":"Narkcham","year":"2021","unstructured":"Narkcham S,\nMody DR,\nJones A,\nThrall MJ. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping. J Am Soc Cytopathol. 2021;10(6):558\u2013564."},{"issue":"1","key":"i1543-2165-150-3-194-b13","series-title":"Arch Pathol Lab Med","first-page":"78","article-title":"Rescreening practices of negative Papanicolaou tests with positive human papillomavirus test result","volume":"146","author":"Goyal","year":"2022","unstructured":"Goyal A,\nDavey DD,\nSouers RJ,\nTabbara SO,\nGoodrich K,\nBooth CN. Rescreening practices of negative Papanicolaou tests with positive human papillomavirus test result. Arch Pathol Lab Med. 2022;146(1):78\u201383."},{"issue":"5","key":"i1543-2165-150-3-194-b14","series-title":"J Am Soc Cytopathol","first-page":"284","article-title":"A review of the FDA-approved molecular testing platforms for human papillomavirus","volume":"8","author":"Salazar","year":"2019","unstructured":"Salazar KL,\nDuhon DJ,\nOlsen R,\nThrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J Am Soc Cytopathol. 2019;8(5):284\u2013292."},{"issue":"5","key":"i1543-2165-150-3-194-b15","series-title":"CA Cancer J Clin","first-page":"458","article-title":"American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: collaborating on the transition to primary HPV screening for cervical cancer in the United States","volume":"73","author":"Downs","year":"2023","unstructured":"Downs LS Jr,\nNayar R,\nGerndt J,\nSaslow D, American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: collaborating on the transition to primary HPV screening for cervical cancer in the United States. CA Cancer J Clin. 2023;73(5):458\u2013460."},{"issue":"2","key":"i1543-2165-150-3-194-b16","series-title":"J Low Genit Tract Dis","first-page":"124","article-title":"Recommendations for use of p16\/Ki67 dual stain for management of individuals testing positive for human papillomavirus","volume":"28","author":"Clarke","year":"2024","unstructured":"Clarke MA,\nWentzensen N,\nPerkins RB, et al. Recommendations for use of p16\/Ki67 dual stain for management of individuals testing positive for human papillomavirus. J Low Genit Tract Dis. 2024;28(2):124\u2013130."},{"issue":"5","key":"i1543-2165-150-3-194-b17","series-title":"CA Cancer J Clin","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","unstructured":"Fontham ETH,\nWolf AMD,\nChurch TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321\u2013346."},{"issue":"2","key":"i1543-2165-150-3-194-b18","series-title":"J Low Genit Tract Dis","first-page":"102","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors","volume":"24","author":"Perkins","year":"2020","unstructured":"Perkins RB,\nGuido RS,\nCastle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102\u2013131."},{"issue":"4","key":"i1543-2165-150-3-194-b19","series-title":"Am J Clin Pathol","first-page":"560","article-title":"Follow-up of women with negative Pap test results and abnormal clinical signs or symptoms","volume":"145","author":"Ocque","year":"2016","unstructured":"Ocque R,\nAustin RM. Follow-up of women with negative Pap test results and abnormal clinical signs or symptoms. Am J Clin Pathol. 2016;145(4):560\u2013567."},{"issue":"5","key":"i1543-2165-150-3-194-b20","series-title":"Am J Clin Pathol","first-page":"708","article-title":"Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful","volume":"140","author":"Li","year":"2013","unstructured":"Li Z,\nBarron S,\nHong W,\nKarunamurthy A,\nZhao C. Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful? Am J Clin Pathol. 2013;140(5):708\u2013714."},{"key":"i1543-2165-150-3-194-b21","series-title":"Cytojournal","first-page":"16","article-title":"Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of uterine cervix and Bethesda System","volume":"18","author":"Alrajjal","year":"2021","unstructured":"Alrajjal A,\nPansare V,\nChoudhury MSR,\nKhan MYA,\nShidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of uterine cervix and Bethesda System. Cytojournal. 2021;18:16."},{"issue":"1","key":"i1543-2165-150-3-194-b22","series-title":"Acta Cytol","first-page":"43","article-title":"Herpesvirus mimics: a potential pitfall in endocervical brush specimens","volume":"38","author":"Stowell","year":"1994","unstructured":"Stowell SB,\nWiley CM,\nPowers CN. Herpesvirus mimics: a potential pitfall in endocervical brush specimens. Acta Cytol. 1994;38(1):43\u201350."},{"key":"i1543-2165-150-3-194-b23","series-title":"CAP Today","article-title":"Endometrial cells in Pap tests\u2014when are they significant","author":"Zhao","year":"2013","unstructured":"Zhao C,\nLi Z. Endometrial cells in Pap tests\u2014when are they significant? CAP Today. January 2013."},{"issue":"3","key":"i1543-2165-150-3-194-b24","series-title":"Arch Pathol Lab Med","first-page":"332","article-title":"College of American Pathologists. Hyperchromatic crowded groups in cervical cytology\u2013differing appearances and interpretations in conventional and ThinPrep preparations: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology","volume":"130","author":"Renshaw","year":"2006","unstructured":"Renshaw AA,\nMody DR,\nWang E,\nHaja J,\nColgan TJ, Cytopathology Resource Committee, College of American Pathologists. Hyperchromatic crowded groups in cervical cytology\u2013differing appearances and interpretations in conventional and ThinPrep preparations: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2006;130(3):332\u2013336."},{"issue":"6","key":"i1543-2165-150-3-194-b25","series-title":"Acta Cytol","first-page":"1403","article-title":"Benign glandular cells in posthysterectomy vaginal smears","volume":"42","author":"Tambouret","year":"1998","unstructured":"Tambouret R,\nPitman MB,\nBell DA. Benign glandular cells in posthysterectomy vaginal smears. Acta Cytol. 1998;42(6):1403\u20131408."},{"issue":"1","key":"i1543-2165-150-3-194-b26","series-title":"Arch Pathol Lab Med","first-page":"48","article-title":"Navigating practice issues related to the unsatisfactory cervicovaginal Papanicolaou test: survey results of laboratories participating in the 2020 College of American Pathologists PAP Education Program","volume":"148","author":"Goyal","year":"2024","unstructured":"Goyal A,\nBooth CN,\nSouers RJ, et al. Navigating practice issues related to the unsatisfactory cervicovaginal Papanicolaou test: survey results of laboratories participating in the 2020 College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2024;148(1):48\u201354."},{"issue":"6 suppl","key":"i1543-2165-150-3-194-b27","series-title":"Contraception","first-page":"S48","article-title":"IUDs and colonization or infection with Actinomyces","volume":"75","author":"Westhoff","year":"2007","unstructured":"Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception. 2007;75(6 suppl):S48\u2013S50."},{"issue":"2","key":"i1543-2165-150-3-194-b28","series-title":"Arch Pathol Lab Med","first-page":"164","article-title":"The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1","volume":"137","author":"Clary","year":"2013","unstructured":"Clary KM,\nDavey DD,\nNaryshkin S, et al. The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1. Arch Pathol Lab Med. 2013;137(2):164\u2013174."},{"issue":"3","key":"i1543-2165-150-3-194-b29","series-title":"Am J Clin Pathol","first-page":"331","article-title":"An analysis of factors that influence the ASCUS\/SIL ratio of pathologists","volume":"116","author":"Juskevicius","year":"2001","unstructured":"Juskevicius R,\nZou KH,\nCibas ES. An analysis of factors that influence the ASCUS\/SIL ratio of pathologists. Am J Clin Pathol. 2001;116(3):331\u2013335."},{"key":"i1543-2165-150-3-194-b30","series-title":"The Bethesda System for Reporting Cervical\/Vaginal Cytologic Diagnoses","first-page":"34","author":"Kurman","year":"1994","unstructured":"Kurman RJ,\nSolomon D. The Bethesda System for Reporting Cervical\/Vaginal Cytologic Diagnoses. New York: Springer Verlag; 1994:34."},{"key":"i1543-2165-150-3-194-b31","article-title":"Accreditation Checklists","author":"College of American Pathologists.","year":"2024","unstructured":"College of American Pathologists. Accreditation Checklists. cap.org. https:\/\/www.cap.org\/laboratory-improvement\/accreditation\/accreditation-checklists. Accessed July 25, 2024."},{"issue":"6","key":"i1543-2165-150-3-194-b32","series-title":"Am J Clin Pathol","first-page":"776","article-title":"ASC\/SIL ratio for cytotechnologists: a surrogate marker of screening sensitivity","volume":"131","author":"Renshaw","year":"2009","unstructured":"Renshaw AA,\nDesch\u00eanes M,\nAuger M. ASC\/SIL ratio for cytotechnologists: a surrogate marker of screening sensitivity. Am J Clin Pathol. 2009;131(6):776\u2013781."},{"key":"i1543-2165-150-3-194-b33","series-title":"J Natl Cancer Inst","first-page":"293","article-title":"ALTS study group comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial","volume":"93","author":"Solomon","year":"2001","unstructured":"Solomon D,\nSchiffman M,\nTarone R. ALTS study group comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293\u2013299."},{"issue":"10","key":"i1543-2165-150-3-194-b34","series-title":"Arch Pathol Lab Med","first-page":"1525","article-title":"The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions","volume":"131","author":"Tworek","year":"2007","unstructured":"Tworek JA,\nJones BA,\nRaab S,\nClary KM,\nWalsh MK. The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions. Arch Pathol Lab Med. 2007;131(10):1525\u20131531."},{"issue":"11","key":"i1543-2165-150-3-194-b35","series-title":"Diagn Cytopathol","first-page":"914","article-title":"HPV test result monitoring of different Bethesda categories in gynaecologic cytology: a valuable quality assurance measure","volume":"46","author":"Goyal","year":"2018","unstructured":"Goyal A,\nStreet J,\nAlperstein SA,\nSiddiqui MT. HPV test result monitoring of different Bethesda categories in gynaecologic cytology: a valuable quality assurance measure. Diagn Cytopathol. 2018;46(11):914\u2013918."},{"issue":"1","key":"i1543-2165-150-3-194-b36","series-title":"Am J Clin Pathol","first-page":"97","article-title":"Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US\/SIL ratio in evaluating the performance of cytopathologists","volume":"129","author":"Cibas","year":"2008","unstructured":"Cibas ES,\nZou KH,\nCrum CP,\nKuo F. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US\/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol. 2008;129(1):97\u2013101."},{"issue":"2","key":"i1543-2165-150-3-194-b37","series-title":"Am J Clin Pathol","first-page":"281","article-title":"Assisted primary screening using the automated ThinPrep Imaging System","volume":"123","author":"Biscotti","year":"2005","unstructured":"Biscotti CV,\nDawson AE,\nDziura B, et al. Assisted primary screening using the automated ThinPrep Imaging System. Am J Clin Pathol. 2005;123(2):281\u2013287."},{"issue":"1","key":"i1543-2165-150-3-194-b38","series-title":"Arch Pathol Lab Med","first-page":"52","article-title":"Current state of cytologic-histologic correlation implementation for North American and international laboratories: results of the College of American Pathologists Committee Laboratory Practices in Gynecologic Cytology Survey","volume":"147","author":"Nguyen","year":"2023","unstructured":"Nguyen LN,\nCrothers BA,\nDavey DD, et al. Current state of cytologic-histologic correlation implementation for North American and international laboratories: results of the College of American Pathologists Committee Laboratory Practices in Gynecologic Cytology Survey. Arch Pathol Lab Med. 2023;147(1):52\u201361."},{"key":"i1543-2165-150-3-194-b01","article-title":"Clinical Laboratory Improvement Amendments (CLIA)","author":"Centers for Disease Control and Prevention","unstructured":"Centers for Disease Control and Prevention. Clinical Laboratory Improvement Amendments (CLIA). cdc.gov. https:\/\/www.cdc.gov\/clia\/php\/about\/#cdc_program_profile_policy-laws-and-regulations. Accessed October 28, 2024."},{"issue":"3","key":"i1543-2165-150-3-194-b02","series-title":"Clin Lab Med","first-page":"739","article-title":"Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part I","volume":"13","author":"Bachner","year":"1993","unstructured":"Bachner P,\nHamlin W. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part I. Clin Lab Med. 1993;13(3):739\u2013752."},{"issue":"4","key":"i1543-2165-150-3-194-b03","series-title":"Clin Lab Med","first-page":"987","article-title":"Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part II","volume":"13","author":"Bachner","year":"1993","unstructured":"Bachner P,\nHamlin W. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988\u2013Part II. Clin Lab Med. 1993;13(4):987\u2013994."},{"issue":"2","key":"i1543-2165-150-3-194-b04","series-title":"Arch Pathol Lab Med","first-page":"158","article-title":"College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization","volume":"137","author":"Tworek","year":"2013","unstructured":"Tworek JA,\nHenry MR,\nBlond B,\nJones BA. College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization. Arch Pathol Lab Med. 2013;137(2):158\u2013163."},{"issue":"1","key":"i1543-2165-150-3-194-b05","series-title":"Diagn Cytopathol","first-page":"84","article-title":"Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure","volume":"14","author":"Tabbara","year":"1996","unstructured":"Tabbara SO,\nSidawy MK. Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure. Diagn Cytopathol. 1996;14(1):84\u201386."},{"issue":"2","key":"i1543-2165-150-3-194-b06","series-title":"Clin Lab Manage Rev","first-page":"91","article-title":"The utility and cost-effectiveness of Pap test rescreening","volume":"12","author":"Raab","year":"1998","unstructured":"Raab SS. The utility and cost-effectiveness of Pap test rescreening. Clin Lab Manage Rev. 1998;12(2):91\u201396."},{"issue":"6","key":"i1543-2165-150-3-194-b07","series-title":"Am J Clin Pathol","first-page":"754","article-title":"Quality assurance in gynecologic cytology: what is practical","volume":"94","author":"Rohr","year":"1990","unstructured":"Rohr LR. Quality assurance in gynecologic cytology: what is practical? Am J Clin Pathol. 1990;94(6):754\u2013758."},{"issue":"4","key":"i1543-2165-150-3-194-b08","series-title":"Am J Clin Pathol","first-page":"494","article-title":"NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA: focused rescreening prior to report issuance, an enhanced quality control measure","volume":"141","author":"Cormier","year":"2014","unstructured":"Cormier K,\nSchaaf M,\nHamilton S,\nTickman RJ,\nPerez-Reyes N,\nSturgis CD. NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA: focused rescreening prior to report issuance, an enhanced quality control measure. Am J Clin Pathol. 2014;141(4):494\u2013500."},{"issue":"9B","key":"i1543-2165-150-3-194-b09","series-title":"J Cell Mol Med","first-page":"4051","article-title":"Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection","volume":"13","author":"Depuydt","year":"2009","unstructured":"Depuydt CE,\nArbyn M,\nBenoy IH,\nVandepitte J,\nVereecken AJ,\nBogers JJ. Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection? J Cell Mol Med. 2009;13(9B):4051\u20134060."},{"issue":"1","key":"i1543-2165-150-3-194-b10","series-title":"Cancer Cytopathol","first-page":"60","article-title":"Knowledge of the HPV status biases cytotechnologists\u2019 interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy","volume":"125","author":"Doxtader","year":"2017","unstructured":"Doxtader EE,\nBrainard JA,\nUnderwood D,\nChute DJ. Knowledge of the HPV status biases cytotechnologists\u2019 interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy. Cancer Cytopathol. 2017;125(1):60\u201369."},{"issue":"9","key":"i1543-2165-150-3-194-b11","series-title":"Arch Pathol Lab Med","first-page":"1182","article-title":"The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known","volume":"138","author":"Moriarty","year":"2014","unstructured":"Moriarty AT,\nNayar R,\nArnold T, et al. The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med. 2014;138(9):1182\u20131185."},{"issue":"6","key":"i1543-2165-150-3-194-b12","series-title":"J Am Soc Cytopathol","first-page":"558","article-title":"Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping","volume":"10","author":"Narkcham","year":"2021","unstructured":"Narkcham S,\nMody DR,\nJones A,\nThrall MJ. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping. J Am Soc Cytopathol. 2021;10(6):558\u2013564."},{"issue":"1","key":"i1543-2165-150-3-194-b13","series-title":"Arch Pathol Lab Med","first-page":"78","article-title":"Rescreening practices of negative Papanicolaou tests with positive human papillomavirus test result","volume":"146","author":"Goyal","year":"2022","unstructured":"Goyal A,\nDavey DD,\nSouers RJ,\nTabbara SO,\nGoodrich K,\nBooth CN. Rescreening practices of negative Papanicolaou tests with positive human papillomavirus test result. Arch Pathol Lab Med. 2022;146(1):78\u201383."},{"issue":"5","key":"i1543-2165-150-3-194-b14","series-title":"J Am Soc Cytopathol","first-page":"284","article-title":"A review of the FDA-approved molecular testing platforms for human papillomavirus","volume":"8","author":"Salazar","year":"2019","unstructured":"Salazar KL,\nDuhon DJ,\nOlsen R,\nThrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J Am Soc Cytopathol. 2019;8(5):284\u2013292."},{"issue":"5","key":"i1543-2165-150-3-194-b15","series-title":"CA Cancer J Clin","first-page":"458","article-title":"American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: collaborating on the transition to primary HPV screening for cervical cancer in the United States","volume":"73","author":"Downs","year":"2023","unstructured":"Downs LS Jr,\nNayar R,\nGerndt J,\nSaslow D, American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: collaborating on the transition to primary HPV screening for cervical cancer in the United States. CA Cancer J Clin. 2023;73(5):458\u2013460."},{"issue":"2","key":"i1543-2165-150-3-194-b16","series-title":"J Low Genit Tract Dis","first-page":"124","article-title":"Recommendations for use of p16\/Ki67 dual stain for management of individuals testing positive for human papillomavirus","volume":"28","author":"Clarke","year":"2024","unstructured":"Clarke MA,\nWentzensen N,\nPerkins RB, et al. Recommendations for use of p16\/Ki67 dual stain for management of individuals testing positive for human papillomavirus. J Low Genit Tract Dis. 2024;28(2):124\u2013130."},{"issue":"5","key":"i1543-2165-150-3-194-b17","series-title":"CA Cancer J Clin","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","unstructured":"Fontham ETH,\nWolf AMD,\nChurch TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321\u2013346."},{"issue":"2","key":"i1543-2165-150-3-194-b18","series-title":"J Low Genit Tract Dis","first-page":"102","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors","volume":"24","author":"Perkins","year":"2020","unstructured":"Perkins RB,\nGuido RS,\nCastle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102\u2013131."},{"issue":"4","key":"i1543-2165-150-3-194-b19","series-title":"Am J Clin Pathol","first-page":"560","article-title":"Follow-up of women with negative Pap test results and abnormal clinical signs or symptoms","volume":"145","author":"Ocque","year":"2016","unstructured":"Ocque R,\nAustin RM. Follow-up of women with negative Pap test results and abnormal clinical signs or symptoms. Am J Clin Pathol. 2016;145(4):560\u2013567."},{"issue":"5","key":"i1543-2165-150-3-194-b20","series-title":"Am J Clin Pathol","first-page":"708","article-title":"Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful","volume":"140","author":"Li","year":"2013","unstructured":"Li Z,\nBarron S,\nHong W,\nKarunamurthy A,\nZhao C. Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful? Am J Clin Pathol. 2013;140(5):708\u2013714."},{"key":"i1543-2165-150-3-194-b21","series-title":"Cytojournal","first-page":"16","article-title":"Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of uterine cervix and Bethesda System","volume":"18","author":"Alrajjal","year":"2021","unstructured":"Alrajjal A,\nPansare V,\nChoudhury MSR,\nKhan MYA,\nShidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of uterine cervix and Bethesda System. Cytojournal. 2021;18:16."},{"issue":"1","key":"i1543-2165-150-3-194-b22","series-title":"Acta Cytol","first-page":"43","article-title":"Herpesvirus mimics: a potential pitfall in endocervical brush specimens","volume":"38","author":"Stowell","year":"1994","unstructured":"Stowell SB,\nWiley CM,\nPowers CN. Herpesvirus mimics: a potential pitfall in endocervical brush specimens. Acta Cytol. 1994;38(1):43\u201350."},{"key":"i1543-2165-150-3-194-b23","series-title":"CAP Today","article-title":"Endometrial cells in Pap tests\u2014when are they significant","author":"Zhao","year":"2013","unstructured":"Zhao C,\nLi Z. Endometrial cells in Pap tests\u2014when are they significant? CAP Today. January 2013."},{"issue":"3","key":"i1543-2165-150-3-194-b24","series-title":"Arch Pathol Lab Med","first-page":"332","article-title":"College of American Pathologists. Hyperchromatic crowded groups in cervical cytology\u2013differing appearances and interpretations in conventional and ThinPrep preparations: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology","volume":"130","author":"Renshaw","year":"2006","unstructured":"Renshaw AA,\nMody DR,\nWang E,\nHaja J,\nColgan TJ, Cytopathology Resource Committee, College of American Pathologists. Hyperchromatic crowded groups in cervical cytology\u2013differing appearances and interpretations in conventional and ThinPrep preparations: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2006;130(3):332\u2013336."},{"issue":"6","key":"i1543-2165-150-3-194-b25","series-title":"Acta Cytol","first-page":"1403","article-title":"Benign glandular cells in posthysterectomy vaginal smears","volume":"42","author":"Tambouret","year":"1998","unstructured":"Tambouret R,\nPitman MB,\nBell DA. Benign glandular cells in posthysterectomy vaginal smears. Acta Cytol. 1998;42(6):1403\u20131408."},{"issue":"1","key":"i1543-2165-150-3-194-b26","series-title":"Arch Pathol Lab Med","first-page":"48","article-title":"Navigating practice issues related to the unsatisfactory cervicovaginal Papanicolaou test: survey results of laboratories participating in the 2020 College of American Pathologists PAP Education Program","volume":"148","author":"Goyal","year":"2024","unstructured":"Goyal A,\nBooth CN,\nSouers RJ, et al. Navigating practice issues related to the unsatisfactory cervicovaginal Papanicolaou test: survey results of laboratories participating in the 2020 College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2024;148(1):48\u201354."},{"issue":"6 suppl","key":"i1543-2165-150-3-194-b27","series-title":"Contraception","first-page":"S48","article-title":"IUDs and colonization or infection with Actinomyces","volume":"75","author":"Westhoff","year":"2007","unstructured":"Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception. 2007;75(6 suppl):S48\u2013S50."},{"issue":"2","key":"i1543-2165-150-3-194-b28","series-title":"Arch Pathol Lab Med","first-page":"164","article-title":"The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1","volume":"137","author":"Clary","year":"2013","unstructured":"Clary KM,\nDavey DD,\nNaryshkin S, et al. The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1. Arch Pathol Lab Med. 2013;137(2):164\u2013174."},{"issue":"3","key":"i1543-2165-150-3-194-b29","series-title":"Am J Clin Pathol","first-page":"331","article-title":"An analysis of factors that influence the ASCUS\/SIL ratio of pathologists","volume":"116","author":"Juskevicius","year":"2001","unstructured":"Juskevicius R,\nZou KH,\nCibas ES. An analysis of factors that influence the ASCUS\/SIL ratio of pathologists. Am J Clin Pathol. 2001;116(3):331\u2013335."},{"key":"i1543-2165-150-3-194-b30","series-title":"The Bethesda System for Reporting Cervical\/Vaginal Cytologic Diagnoses","first-page":"34","author":"Kurman","year":"1994","unstructured":"Kurman RJ,\nSolomon D. The Bethesda System for Reporting Cervical\/Vaginal Cytologic Diagnoses. New York: Springer Verlag; 1994:34."},{"key":"i1543-2165-150-3-194-b31","article-title":"Accreditation Checklists","author":"College of American Pathologists.","year":"2024","unstructured":"College of American Pathologists. Accreditation Checklists. cap.org. https:\/\/www.cap.org\/laboratory-improvement\/accreditation\/accreditation-checklists. Accessed July 25, 2024."},{"issue":"6","key":"i1543-2165-150-3-194-b32","series-title":"Am J Clin Pathol","first-page":"776","article-title":"ASC\/SIL ratio for cytotechnologists: a surrogate marker of screening sensitivity","volume":"131","author":"Renshaw","year":"2009","unstructured":"Renshaw AA,\nDesch\u00eanes M,\nAuger M. ASC\/SIL ratio for cytotechnologists: a surrogate marker of screening sensitivity. Am J Clin Pathol. 2009;131(6):776\u2013781."},{"key":"i1543-2165-150-3-194-b33","series-title":"J Natl Cancer Inst","first-page":"293","article-title":"ALTS study group comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial","volume":"93","author":"Solomon","year":"2001","unstructured":"Solomon D,\nSchiffman M,\nTarone R. ALTS study group comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293\u2013299."},{"issue":"10","key":"i1543-2165-150-3-194-b34","series-title":"Arch Pathol Lab Med","first-page":"1525","article-title":"The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions","volume":"131","author":"Tworek","year":"2007","unstructured":"Tworek JA,\nJones BA,\nRaab S,\nClary KM,\nWalsh MK. The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions. Arch Pathol Lab Med. 2007;131(10):1525\u20131531."},{"issue":"11","key":"i1543-2165-150-3-194-b35","series-title":"Diagn Cytopathol","first-page":"914","article-title":"HPV test result monitoring of different Bethesda categories in gynaecologic cytology: a valuable quality assurance measure","volume":"46","author":"Goyal","year":"2018","unstructured":"Goyal A,\nStreet J,\nAlperstein SA,\nSiddiqui MT. HPV test result monitoring of different Bethesda categories in gynaecologic cytology: a valuable quality assurance measure. Diagn Cytopathol. 2018;46(11):914\u2013918."},{"issue":"1","key":"i1543-2165-150-3-194-b36","series-title":"Am J Clin Pathol","first-page":"97","article-title":"Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US\/SIL ratio in evaluating the performance of cytopathologists","volume":"129","author":"Cibas","year":"2008","unstructured":"Cibas ES,\nZou KH,\nCrum CP,\nKuo F. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US\/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol. 2008;129(1):97\u2013101."},{"issue":"2","key":"i1543-2165-150-3-194-b37","series-title":"Am J Clin Pathol","first-page":"281","article-title":"Assisted primary screening using the automated ThinPrep Imaging System","volume":"123","author":"Biscotti","year":"2005","unstructured":"Biscotti CV,\nDawson AE,\nDziura B, et al. Assisted primary screening using the automated ThinPrep Imaging System. Am J Clin Pathol. 2005;123(2):281\u2013287."},{"issue":"1","key":"i1543-2165-150-3-194-b38","series-title":"Arch Pathol Lab Med","first-page":"52","article-title":"Current state of cytologic-histologic correlation implementation for North American and international laboratories: results of the College of American Pathologists Committee Laboratory Practices in Gynecologic Cytology Survey","volume":"147","author":"Nguyen","year":"2023","unstructured":"Nguyen LN,\nCrothers BA,\nDavey DD, et al. Current state of cytologic-histologic correlation implementation for North American and international laboratories: results of the College of American Pathologists Committee Laboratory Practices in Gynecologic Cytology Survey. Arch Pathol Lab Med. 2023;147(1):52\u201361."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/3\/article-p194.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/doi\/10.5858\/arpa.2025-0187-CP\/3541720\/10.5858_arpa.2025-0187-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/3\/article-p194.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/3\/article-p194.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:27:37Z","timestamp":1772076457000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/3\/article-p194.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":76,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2025-0187-cp","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}